INCR Stock Analysis: Buy, Sell, or Hold?
INCR - Intercure Ltd. Ordinary Shares
$0.87
0.02 (2.46%)
▲
5d:
-17.05%
30d:
+7.53%
90d:
+10.25%
WAIT
LOW Confidence
Analysis Updated: Jun 11, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When INCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: INCR is down 17.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: INCR is down 17.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: INCR is currently trading at $0.87, which is considered fair relative to its 30-day fair value range of $0.81 to $1.02.
Technical Outlook: Technically, INCR is showing sideways momentum. The price is currently testing key support at $0.92. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $33.56 (+3753.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INCR is showing sideways momentum. The price is currently testing key support at $0.92. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $33.56 (+3753.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.81 -
$1.02
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 3753.0% below Wall St target ($33.56)
- WARNING: Recommendation downgraded due to -17.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.81 -
$1.02
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.92
Resistance Level
$1.23
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.18
Wall Street Target
$33.56
(+3753.0%)
Revenue Growth (YoY)
23.9%
Earnings Growth (YoY)
-84.7%
Profit Margin
-13.2%
Share & Embed Analysis
Last updated: June 12, 2026 8:04 AM ET
Data refreshes hourly during market hours. Next update: 9:04 AM
Data refreshes hourly during market hours. Next update: 9:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$193 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 58 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$66 | 66 BUY |
